Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Inflammatory Bowel Diseases|February 2, 2012
Pretravel preparation and travel-related morbidity in patients with inflammatory bowel diseaseDarius Soonawala, Anna M van Eggermond, Herma Fidder, et al.Clinical Imaging|October 28, 2009
Contrast-enhanced CT colonography with 64-slice MDCT compared to endoscopic colonoscopy in the follow-up of patients after colorectal cancer resectionMarianne Michal Amitai, Herma Fidder, Benjamin Avidan, et al.Digestion|September 21, 2005
Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsedYoram Menachem, Benjamin Avidan, Alexandra Lavy, et al.Circulation. Arrhythmia and Electrophysiology|May 11, 2017
Acute and Long-Term Effects of Full-Power Electroporation Ablation Directly on the Porcine EsophagusKars Neven, René van Es, Vincent van Driel, et al.Journal of Gastroenterology and Hepatology|March 3, 2006
Endoscopic ultrasound staging of rectal cancer: diagnostic value before and following chemoradiationYaakov Maor, Moshe Nadler, Iris Barshack, et al.The American Journal of Gastroenterology|March 17, 2011
Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort studyChristine Breynaert, Marc Ferrante, Herma Fidder, et al.The American Journal of Gastroenterology|May 19, 2007
Risk factors for perianal Crohn's disease: the role of genotype, phenotype, and ethnicityAmir Karban, Maza Itay, Ofir Davidovich, et al.The American Journal of Gastroenterology|January 26, 2005
The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's diseaseHerma Fidder, Yehuda Chowers, Zvi Ackerman, et al.Inflammatory Bowel Diseases|April 3, 2009
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's diseaseFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.Inflammatory Bowel Diseases|August 11, 2011
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.Pageof 2